About the company

Senzime AB is a high-tech company based in Uppsala, Sweden. The company develops and markets a unique and proprietary enzyme based biosensor technology with a wide applicability throughout different medical and bio/chemical processes and industries.

Senzime focuses the following application areas:

• Medical diagnostic instruments (Point-of-care and other diagnostics)

• Pharmaceutical industry (bio reactor control, drug development etc.)  

• Chemical processing, (biofuel etc.)

• Food & Beverage processing (e.g. urea measurement in milk and dairy processes)

Started in 1999 as a development company, Senzime is currently focused on ramping up production and delivery capabilities.

Our team:

Staffan Boström, CEO since 2002, Licentiate degree of Science in Chemical Engineering, 1989-2001 Co-founder and Managing Director of NEK Kabel AB.

Thomas Carlsson, Technical Director since 1999 (Inventor and co-founder). MSc in Biotechnology. Various positions within the biotechnological field since 1990.

Martin Boström, Development manager since 2002. MScEE. 1989-2002 leading positions, e.g. Nokia Mobile Phones, Technical Manager, Mici Elektronik, Development Manager.

Rianne Waninge, PhD in Food technology science/ biophysical chemistry from Lund University in 2004. Starting at Senzime in January 2008, Rianne has responsibility for the further development and verification of Senzime’s proprietary sensor technology.

Board of Directors:

Adam Dahlberg, Chairman, (born 1973, MSc Business Administration)
Adam is working with investments, made by himself and together with other members of the Crafoord family (Holger Crafoord founded Swedish success med tech company Gambro). He deploys an active investment strategy within early phases of several areas of advanced technology, including companies such as QlikTechnologies Inc. (the worlds fastest growing Business Intelligence software company, employing appr. 400 people), PiezoMotor AB (revolutionary micro motor company, employing appr 35 people), Corline Systems AB (a cell therapy company delivering a unique enabling technology for diabetes therapy).

Lars Wiklund, Professor and Senior Physician in anesthesia and intensive care at Uppsala University and Uppsala University Hospital. Head of the Department of Surgical Science. Since the 1970s, active in circulation and metabolic research, as well as ischemic brain and heart damage caused by cardiac arrest. Lars Wiklund has also studied the turnover of blood-borne metabolites, i.e. glucose, in connection with surgery and intensive care.

Staffan Boström, CEO of Senzime, see ’Team’

Thomas Carlsson, Technical Director, see ‘Team’

Henrik Nittmar (born 1966, MSc Industrial Engineering, PhD Business Administration)
Henrik works as an investment manager for a select number of clients and sits on the board of several companies within the high tech industry areas. Having done research within Innovation Management at Stockholm School of Economics and a professional background within management and brand consultancy, Henrik has a focus on developing Senzime from a financing and marketing/sales related perspective.

Dag Thulin (born 1944)
Dag has an industrial background with profound knowledge of marketing and sales in an industrial setting as well as developing his own successful company within the special cable industry where he also served as CEO. After divesting his company in 2002, Dag is focusing his professional time on the board of Senzime.